 Edesa Biotech Inc NASDAQ: EDSA is trading higher Tuesday after the company announced additional results from the Phase 2 part of the ongoing Phase 23 study of EB05 in COVID-19. Edesa reported that EB05 demonstrated mortality reductions in multiple patient groups beyond the initial findings. 